Cefuroxime description: Difference between revisions
Created page with "__NOTOC__ {{Cefuroxime}} {{CMG}};{{AE}}{{AK}} Cefuroxime is a semisynthetic, broad-spectrum, cephalosporin antibiotic for parenteral administration. It is the sodium salt of ..." |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Cefuroxime}} | {{Cefuroxime}} | ||
{{CMG}};{{AE}}{{AK}} | {{CMG}};{{AE}}{{AK}} | ||
Cefuroxime is a semisynthetic, broad-spectrum, cephalosporin antibiotic for parenteral administration. It is the sodium salt of (6R,7R)-3-carbamoyloxymethyl-7-[Z-2-methoxyimino-2-(fur-2-yl)acetamido]ceph-3-em-4-carboxylate, and it has the following chemical structure: | Cefuroxime is a semisynthetic, broad-spectrum, cephalosporin antibiotic for parenteral administration. It is the sodium salt of (6R,7R)-3-carbamoyloxymethyl-7-[Z-2-methoxyimino-2-(fur-2-yl)acetamido]ceph-3-em-4-carboxylate, and it has the following chemical structure: | ||
Revision as of 07:04, 4 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Cefuroxime is a semisynthetic, broad-spectrum, cephalosporin antibiotic for parenteral administration. It is the sodium salt of (6R,7R)-3-carbamoyloxymethyl-7-[Z-2-methoxyimino-2-(fur-2-yl)acetamido]ceph-3-em-4-carboxylate, and it has the following chemical structure:
The empirical formula is C16H15N4NaO8S, representing a molecular weight of 446.4.
ZINACEF contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.
ZINACEF in sterile crystalline form is supplied in vials equivalent to 750 mg, 1.5 g, or 7.5 g of cefuroxime as cefuroxime sodium and in ADD-Vantage® vials equivalent to 750 mg or 1.5 g of cefuroxime as cefuroxime sodium. Solutions of ZINACEF range in color from light yellow to amber, depending on the concentration and diluent used. The pH of freshly constituted solutions usually ranges from 6 to 8.5.
ZINACEF is available as a frozen, iso-osmotic, sterile, nonpyrogenic solution with 750 mg or 1.5 g of cefuroxime as cefuroxime sodium. Approximately 1.4 g of Dextrose Hydrous, USP has been added to the 750-mg dose to adjust the osmolality. Sodium Citrate Hydrous, USP has been added as a buffer (300 mg and 600 mg to the 750-mg and 1.5-g doses, respectively). ZINACEF contains approximately 111 mg (4.8 mEq) and 222 mg (9.7 mEq) of sodium in the 750-mg and 1.5-g doses, respectively. The pH has been adjusted with hydrochloric acid and may have been adjusted with sodium hydroxide. Solutions of premixed ZINACEF range in color from light yellow to amber. The solution is intended for intravenous (IV) use after thawing to room temperature. The osmolality of the solution is approximately 300 mOsmol/kg, and the pH of thawed solutions ranges from 5 to 7.5.
The plastic container for the frozen solution is fabricated from a specially designed multilayer plastic, PL 2040. Solutions are in contact with the polyethylene layer of this container and can leach out certain chemical components of the plastic in very small amounts within the expiration period. The suitability of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/50643s11lbl.pdf